(Q43241918)

17 November 2017

title

Desirudin dosing and monitoring in moderate renal impairment (English)

1 reference

17 November 2017

Anne N Nafziger

1

1 reference

17 November 2017

Joseph S Bertino

series ordinal

2

1 reference

17 November 2017

publication date

13 November 2009

1 reference

The Journal of Clinical Pharmacology

17 November 2017

published in

1 reference

17 November 2017

volume

50

1 reference

17 November 2017

issue

6

1 reference

17 November 2017

page(s)

614-622

1 reference

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Desirudin: a review of its use in the management of thrombotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Catabolism of hirudin and thrombin-hirudin complexes in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Hirudins: antithrombin anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

The role of recombinant hirudins in the management of thrombotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Hirudin in renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009350626

21 January 2018

Identifiers

DOI

10.1177/0091270009350626

1 reference

17 November 2017

1 reference